AbbVie Inc (ABBV) stock saw a decline, ending the day at $176.2 which represents a decrease of $-1.81 or -1.02% from the prior close of $178.01. The stock opened at $177.02 and touched a low of ...

AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...

Macroeconomic factors have weighed on US stocks in the final days of the year, with the broader market declining by over 1% ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

The global antiviral drugs market is poised for consistent growth, projected to expand at a compound annual growth rate (CAGR ...

We recently compiled a list of the 10 Best Dividend Growth Stocks to Buy and Hold in 2025. In this article, we are going to ...

AbbVie Inc (ABBV) stock saw a decline, ending the day at $178.01 which represents a decrease of $-1.19 or -0.66% from the prior close of $179.2. The stock opened at $177.92 and touched a low of ...

This was the stock's second consecutive day of losses.

The stock's fall snapped a three-day winning streak.

Aldeyra Therapeutics is finally nearing commercialization, attracting renewed attention from some analyst firms. Explore more ...

Schwab and Vanguard are both giants in the investment arena. Retirees who are considering between the two should base ...

The acquisition of Karuna Therapeutics Inc. by Bristol Myers Squibb Co. (BMS) was announced in December 2023, and closed as the BioEurope Spring meeting was convening in March. Along with the ...